Compound News and Research

RSS

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Common antiwrinkle product compound causes reaction in skin cells

Researchers from Universit, Laval's Faculty of Medicine have discovered that a compound commonly used in many antiwrinkle products causes a pathological reaction in skin cells.

12 Apr 2007

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Gene finding could lead to new pathways for development of Alzheimer's therapeutics

Scientists have known for more than a decade that individuals with a certain gene are at higher risk for developing Alzheimer's disease.

11 Apr 2007

Protecting brains of premature infants - new approach needed

A study of how the brain of a premature infant responds to injury has found vulnerabilities similar to those in the mature brain but also identified at least one significant difference, according to neuroscientists and neonatologists at Washington University School of Medicine in St. Louis.

11 Apr 2007

Arsenic-based additive used in chicken feed may pose health risks to humans

Pets may not be the only organisms endangered by some food additives.

10 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

Method for making new molecules based on flavonoids - implications for cancer therapeutics

You've heard of them -- the good-for-your-health compounds found in plants that we enjoy in red wine, dark chocolate, green tea and citrus fruits.

5 Apr 2007

NewYork-Presbyterian and AstraZeneca collaborate in series of cancer studies

NewYork-Presbyterian Hospital is one of six centers nationally to be selected for collaboration with AstraZeneca for an ongoing series of Phase II clinical trials of various novel compounds for potential treatment of a wide variety of cancers.

5 Apr 2007

Targeted therapies improve colon cancer survival rates

People diagnosed with advanced colorectal cancer that has spread to distant organs, such as White House spokesman Tony Snow, are much more likely to survive today than even just a few years ago, due to the recent and continued emergence of improved therapies, say cancer experts.

3 Apr 2007

Eli Lilly acquires Hypnion

Eli Lilly and Company has announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

3 Apr 2007

Fungal compound galiellalactone may combat prostate cancer

Can a substance from a fungus that grows on decaying trees provide a cure for aggressive prostate cancer? This is the hope of researchers at Lund University in Sweden.

3 Apr 2007

Compounds derived from blue agave may be more effective way to deliver drugs to the colon

Compounds derived from the blue agave, a fruit used to make tequila, shows promise in early laboratory studies as a natural, more effective way to deliver drugs to the colon than conventional drug-carriers, according to chemists at the University of Guadalajara in Mexico.

3 Apr 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

Biobased alternative for critical component of many polymer products

Virginia Tech chemists are looking for biobased alternatives and environmentally friendly reaction pathways to replace a toxic intermediate that is a critical component of many polymer products.

3 Apr 2007

New blood thinner thrombin-receptor antagonist may work without bleeding risk

When studying a new blood thinner, one of the first signs the drug is working is seeing a slight increase in minor bleeding, nose bleeds and bruising, an inconvenient side effect of preventing the blood clots that are the leading cause of heart attack and stroke.

3 Apr 2007

New contrast agent selectively targets and highlights malignant micro-calcifications in the breast

Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.

2 Apr 2007

Study results on bifeprunox in patients with schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week.

2 Apr 2007

Intelligent materials substitute for bone tissue

More than half a million people in the European Union and a million in the United States suffer from disorders in or serious defects of some part of their bone structure.

2 Apr 2007

New discoveries offer promise for cholesterol drugs

New discoveries offer promise for developing drugs that improve on the therapeutic profile of niacin, the inexpensive, time-tested B-vitamin that boosts levels of HDL cholesterol, the good cholesterol with the potential to protect people against heart attacks and stroke, scientists report.

1 Apr 2007